Insulin plus incretin agent combination therapy in type 2 diabetes: a systematic review
R Goldenberg - Current medical research and opinion, 2014 - Taylor & Francis
Background: Insulin and incretin agents (dipeptidyl peptidase-4 inhibitors [DPP4is] and
glucagon-like peptide-1 receptor agonists [GLP1 RAs]) are second-line treatment options in …
glucagon-like peptide-1 receptor agonists [GLP1 RAs]) are second-line treatment options in …
A randomized trial comparing the efficacy and safety of treating patients with type 2 diabetes and highly elevated HbA1c levels with basal‐bolus insulin or a glucagon …
M Abreu, A Tumyan, A Elhassan… - Diabetes, Obesity …, 2019 - Wiley Online Library
Aim To compare the efficacy and safety of a glucagon‐like peptide‐1 receptor agonist
(GLP1RA) plus basal insulin versus basal‐bolus insulin treatment in patients with very …
(GLP1RA) plus basal insulin versus basal‐bolus insulin treatment in patients with very …
Lessons from a diabetes clinic: achieving glycemic goals and clinical use of antidiabetic agents in patients with type 2 diabetes
I Avramidis, A Apsemidou, AZ Lalia, N Petridis… - Clinical …, 2020 - Am Diabetes Assoc
The proportion of patients with type 2 diabetes who achieve their glycemic goals remains
low. We examined medical records and A1C results from patient visits to our referral …
low. We examined medical records and A1C results from patient visits to our referral …